muito exóticos os saltos da próxima estação. o style fez uma seleção dos mais bacanas, eu dos mais absurdos:
1º fila (esquerda pra direita): versace, yves saint lauren, balenciaga, louis vuitton e fendi (de gosto duvidoso...)
2º fila: bruno frisoni, marc jacobs, chanel, pierre hardy e donna karan

o mais importante é que os saltos precisam ser altíssimos. os mais bacanas tem plataforma na frente e salto agulha (tipo balenciaga e ysl). se a plataforma for completa, funciona melhor como anabella. vale lembrar que os flats também tem sua vez, de preferência os de bico pontudo (os redondos são muito meigos). legal também se os sapatos forem metalizado, de cobra ou croco.


8 pgs

fotos: ioram finguerman
styling: olivia hanssen
modelo: elisa joenk
cabelo & make: agnes mamede (hit)

para revista marie claire, edição novembro 2006

tim festival

que bom que os shows do tim acabaram mudando para o tom brasil porque se o som tava ruim no tom, imagina no anhembi... o melhor show da noite pra mim foi o do yeah yeah yeahs. imperdível a karen 0 possuida no palco. absurda. o do tv on the radio foi bom, pena que tocaram muitas músicas do último disco que é um pouco desanimado, mas teve seus momentos empolgantes. já o daft punk tava com o som tão alto que nem consegui escutar. uma pena, é que depois de uma noite longa (o 1º show começou às 20hs e o do daft às 2hs), num calor infernal e sem sentar fica difícil ficar animada até o final.


produzi uma matéria e me mandaram esses colares da pat falcão que eu não conhecia. ela já trabalhou com a giselle nasser e agora faz bijoux. eles são bem bonitinhos, pena que um pouco caros (na faixa de r$ 200)... "medalha sapos", "copacabana", "libélula" e "arara" - meu favorito. só acho que a arara poderia ser mais estilizada e menos com cara de louro josé... pra entrar em contato com ela: contato@patfalcão.com.br


campanhas novas - (a + linda) costume national

julia dunstall (olha a franja aí denovo!) + sofia sachez & mauro mongiello. styling de anastasia barbieri

campanhas novas - aquascutum

julia stegner & mario sorrenti

campanhas novas - fendi

angela lindvall & karl lagerfeld



a lindona da jessica miller para a paul & joe - loja fofita de londres. fotos de camilla äkrans.


raquel lieven (ford), agnes mamede (hit)



pra mim a mais linda do momento é a irina lazareanu.
da esquerda pra direita: gucci, alessandro dell'acqua, etro, balmain e no lindíssimo editorial para a w de outubro chamado czechmate, fotografado por michael thompson.


+ v nova

"São Paulo Fashion Week starts more with a bang than with a whimper. The future of Brazil may depend on what the models have on. By Christopher Bollen
There were two different São Paulo spectacles hitting the city on the week of July 12, 2006—and both were designed, with typical Brazilian sensationalism, to get attention. The first was a series of public-bus firebombings and gun sprayings into local banks and police stations, which left six people dead and provided the city, at least momentarily, with a grim echo of the violence that had paralyzed it two months earlier. Ironically, the guilty were already locked behind bars—kingpins of the notorious prison gang called the First Command of the Capital (PCC), who had taken the threat of several key transfers to a maximum security prison in another state as a call to show officials that they still controlled the streets—even if only by the power of a few phone calls. President Lula, who has long promised to purge the gang rule in a country where justice has often been considered something that gets in the way, and who also happens to be facing a tough re-election bid this year, labeled the faction a “crime industry.” This industry is one of the city and the country’s most prevailing. The violent attacks underscored the brutal social problems that have plagued Brazil as it tries to become a dependable superpower on the global game board"... bafo. o resto da matéria não está no ar então não da pra saber como termina. uó.


saiu a v nova com a penélope cruz na capa. o site tá bem legal, com muitas fotos e textos. adoro a matéria "backstage: ny fashion week". fofa. a "star power" também é bonitinha. de brasil tem alice braga, gisele e são paulo fashion week. vale a pena ver.


matéria fenomenal que saiu na wired desse mês chamada the thin pill. o artigo fala que 75 milhões de americanos tem uma doença chamada "síndrome metabólica", quase uma nova definição para a obesidade. e que esse nome foi criado como uma estratégia de marketing pela indústria farmacêutica para que a própria crie novas drogas, aumentando o seu caixa anual em 18 bilhões de dólares. impressionante.

"Cunningham is among the first wave of Americans to be diagnosed with metabolic syndrome, a condition that, though only concretely defined five years ago, is now said to afflict as many as 75 million Americans – whether they know it or not. We sit, indeed, amid an epidemic of metabolic syndrome, a fact all the more remarkable because so few people are familiar with it. For this is no virus on the loose, no plague that has spread unchecked. Rather, metabolic syndrome is just a new way to think about a cluster of well-known and increasingly prevalent conditions. Metabolic syndrome is characterized by five risk factors: high blood pressure, high blood sugar, high triglycerides (fatty acids in the bloodstream), low HDL ("good") cholesterol, and obesity. Of the five, obesity – which is itself often referred to as an epidemic – is the most important, because the rise of the morbidly overweight is directly driving the rise in the syndrome. Metabolic syndrome is, in fact, almost indistinguishable from obesity – at least 85 percent of those who have the syndrome are obese or overweight.

But is it real? In some ways, no. You can't see metabolic syndrome through a microscope, or detect it through a single blood test. Since it's a checklist of risk factors rather than symptoms, it stretches the way we think of disease. It's very much a human invention, a "syndrome" – that term researchers assign to things they don't quite understand. But in other ways, it's absolutely real. Though championed by drug companies, it's been defined and recognized by legitimate health organizations. And it's definitely unhealthy. You can't die of metabolic syndrome, but you can die of what it leads to: diabetes and heart disease.

Metabolic syndrome, in other words, could be the great disease of our age. Or it could be a sign of how diseased our age is, a demonstration of how certain we are that there is always a scientific explanation, a diagnosis, and perhaps a pill for what ails us. Either way, metabolic syndrome is a disease whose time has come.

That's what makes metabolic syndrome so compelling: It takes personal responsibility out of the equation. Turning the epidemic of obesity into a slightly smaller epidemic of metabolic syndrome puts it in the province of science, not lifestyle. With science, we're not confined to a futile path of diet and exercise. With science, we get drugs.

Should the right drugs come along, the metabolic syndrome market "promises to be as big or bigger" than cholesterol, Pharmaceutical Executive magazine predicted a couple of years ago. And rimonabant, also known by its brand name, Acomplia, may well be the first of those drugs. JP Morgan analysts predict that rimonabant sales could hit $5 billion a year.

In the drug industry, finding disorders like metabolic syndrome is known as "developing new disease markets" or "branding a condition." Industry critics have their own term for it: "disease mongering," they say, shaking a finger at pharmaceutical firms for devising treatments for normal conditions of life – menopause, anxiety, obesity. But as tempting a villain as the drug industry makes, it's not so clear that obesity is, in fact, a normal part of life. Blame corn subsidies or videogames or PepsiCo, but obesity has transformed our nation in the past 30 years. Diet and exercise? It's easy to recommend, and it's good in theory, but there's surprisingly little proof that lifestyle intervention actually works as a weight-loss strategy.

So goes the domino effect of recognition: First the National Institutes of Health and the American Heart Association identify metabolic syndrome as a disease, then the FDA creates an indication, and then the HMOs – which have largely refused to reimburse patients for obesity treatments – agree to pick up the tab for metabolic syndrome prescriptions, thus making physicians more likely to prescribe them for their patients. The only drawback is that the market could be too big: If the HMOs see a diagnosis that fits 75 million Americans and a potential bill for $18 billion, they might simply refuse to pay it.

That, of course, is the demographic ripple effect of diseases like metabolic syndrome. As the medical establishment reaches further down the causal chain to identify more risk factors and spot them earlier, and as it assigns names, definitions, and treatments to these diagnoses, more and more people are swept into the disease net. Add in our genetic biomarkers and it's clear that disease won't be something we can avoid anymore. It will be something we simply have, just as we have freckles or wear glasses. We will all carry our disease portfolios and will be identified through our ailments – or more precisely, our inclinations toward certain ailments. Metabolic syndrome is just the latest step on this path."